Enterprise Value
190.3M
Cash
66.61M
Avg Qtr Burn
-17.54M
Short % of Float
6.15%
Insider Ownership
5.19%
Institutional Own.
52.13%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DEXTENZA® (dexamethasone ophthalmic insert) Details Inflammation and pain following ophthalmic surgery | Approved Quarterly sales | |
ReSure® Sealant Details Intraoperative management of clear corneal incision | Approved Quarterly sales | |
DEXTENZA® (dexamethasone ophthalmic insert) Details Eye disease , Allergic conjunctivitis | Approved Quarterly sales | |
OTX-TKI (axitinib intravitreal implant) Details Wet age-related macular degeneration | Phase 3 Initiation | |
OTX-DED (dexamethasone intracanalicular insert) Details Dry eye disease | Phase 2 Data readout | |
OTX-CSI (cyclosporine intracanalicular insert) Details Dry eye disease | Phase 2 Data readout | |
OTX-TIC (travoprost implant) Details Primary open angle glaucoma , Ocular hypertension | Phase 2 Data readout | |
OTX-TKI (axitinib intravitreal implant) Details Eye disease , Diabetic retinopathy | Phase 1 Data readout |